Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Psychiatric Quarterly
Erschienen in: Psychiatric Quarterly 3/2010

01.09.2010 | Original Paper

Long-Term Use of Pramipexole in Bipolar Depression: A Naturalistic Retrospective Chart Review

verfasst von: Rif S. El-Mallakh, Praveen Penagaluri, Arun Kantamneni, Yonglin Gao, Rona J. Roberts

Erschienen in: Psychiatric Quarterly | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

A naturalistic retrospective chart review of all patients given pramipexole for bipolar depression in addition to their mood stabilizers was undertaken. Sixteen patients were followed for an average of 6.7 ± SD 9.0 months. Half of the patients stopped the pramipexole an average of 2 months after starting it. For all patients, depressed mood, and the total profile of depressive symptoms improved significantly within 4 weeks and remained significantly improved for as long as 36 weeks. Both global function (GAF), and global impression (CGI) improved with pramipexole. Irritability and insomnia both increased slightly initially, and then subsided. There were no changes in mania ratings for up to 36 months. Long-term outcome of adjunctive pramipexole appears to be adequate, with apparent maintenance of effect for over 9 months.
Literatur
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders-Text Revision, 4th edn., revised. Arlington, Virginia, American Psychiatric Press, 2000
2.
Calabrese JR, Bowden CL, Sachs GS, et al.: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression Lamictal 602 study group. Journal of Clinical Psychiatry 60:79–88, 1999PubMed
3.
Calabrese JR, Bowden CL, Sachs GS, et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 64:1013–1024, 2003CrossRefPubMed
4.
Calabrese JR, Keck PE Jr, Macfadden W, et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 162:1351–1360, 2005CrossRefPubMed
5.
Cassano P, Lattanzi L, Soldani F, et al.: Pramipexole in treatment-resistant depression: an extended follow up. Depression and Anxiety 20:131–138, 2004CrossRefPubMed
6.
El-Mallakh RS, Huff MO: Mood stabilizers and ion regulation. Harvard Review of Psychiatry 9:23–32, 2001CrossRefPubMed
7.
El-Mallakh RS, Karippot A: Chronic depression in bipolar disorder. American Journal of Psychiatry 163:1137–1341, 2006CrossRef
8.
El-Mallakh RS, Karippot A, Ghaemi SN: Antidepressants in Bipolar Depression. In: El-Mallakh RS, Ghaemi SN (Eds) Bipolar Depression: A Comprehensive Guide. Washington, DC, American Psychiatric Publishing, Inc., pp. 167–183, 2006
9.
El-Mallakh RS, Weisler RH, Townsend MH, et al.: Bipolar II disorder: current and future treatment options. Annals of Clinical Psychiatry 18:259–266, 2006CrossRefPubMed
10.
Frye MA, Ketter TA, Kimbrell TA, et al.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology 20:607–614, 2000CrossRefPubMed
11.
Ghaemi SN, Boiman EE, Goodwin FK: Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. Journal of Clinical Psychiatry 61:804–808, 2000PubMed
12.
Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME, Filkowski MM, Hennen J, Sachs G, Goodwin FK, Baldessarini RJ: A randomized clinical trial of long-term effectiveness and safety of modern antidepressants combined with mood-stabilizers. Journal of Clinical Psychiatry, 2010 (in press)
13.
Ghaemi SN, Lenox MS, Baldessarini RJ: Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. Journal of Clinical Psychiatry 62:565–569, 2001PubMedCrossRef
14.
Goldberg JF, Burdick KE, Endick CJ: Preliminary randomized, double blind, placebo controlled trial of pramipexole added to mood stabilizers for treatment resistant bipolar depression. American Journal of Psychiatry 161(3):564–566, 2004CrossRefPubMed
15.
Jensen NH, Rodriguiz RM, Caron MG, et al.: N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 33:2303–2312, 2008CrossRefPubMed
16.
Judd LL, Akiskal HS, Schettler PJ, et al.: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry 60:261–269, 2003CrossRefPubMed
17.
Judd LL, Akiskal HS, Schettler PJ, et al.: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 59:530–537, 2002CrossRefPubMed
18.
Kupka RW, Altshuler LL, Nolen WA, et al.: Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disorders 9(5):531–535, 2007CrossRefPubMed
19.
Maj J, Rogóż Z, Margas W, et al.: The effect of repeated treatment with pramipexole on the central dopamine D3 system. Journal of Neural Transmission 107:1369–1379, 2000CrossRefPubMed
20.
Nierenberg AA, Ostacher MJ, Calabrese JR, et al.: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. American Journal of Psychiatry 163:210–216, 2006CrossRefPubMed
21.
Nemeroff CB, Evans DL, Gyulai L, et al.: A double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. American Journal of Psychiatry 158:906–912, 2001PubMed
22.
Post RM, Leverich GS, Nolen WA, et al.: A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disorders 5:396–406, 2003CrossRefPubMed
23.
Roberts RJ, Yang M, El-Mallakh RS: Validity and reliability of the RAPID (Rapid Psychiatric Interview Data) scale. Presented at the Eighth International Conference on Bipolar Disorder, Pittsburgh, Pennsylvania, pp. 25–27, 2009
24.
Sachs GS, Guille C, McMurrich SL: A clinical monitoring form for mood disorders. Bipolar Disorders 4:323–327, 2002CrossRefPubMed
25.
Sachs GS, Nierenberg AA, Calabrese JR, et al.: Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine 356(17):1711–1722, 2007CrossRefPubMed
26.
Spearing MK, Post RM, Leverich GS, et al.: Modification of clinical global impressions (GCI) scale for use in bipolar illness (BP): CGI-BP. Psychiatry Research 73:159–171, 1997CrossRefPubMed
27.
Vieta E, Suppes T, Eggens I, et al.: Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (International Trial 126). Journal of Affective Disorders 109:251–253, 2008CrossRefPubMed
28.
Wermuth L: A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson’s disease. European Journal of Neurology 5:235–242, 1998CrossRefPubMed
29.
Zarate CA Jr, Payne JL, Singh J, et al.: Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry 56(1):54–60, 2004CrossRefPubMed
Metadaten
Titel
Long-Term Use of Pramipexole in Bipolar Depression: A Naturalistic Retrospective Chart Review
verfasst von
Rif S. El-Mallakh
Praveen Penagaluri
Arun Kantamneni
Yonglin Gao
Rona J. Roberts
Publikationsdatum
01.09.2010
Verlag
Springer US
Erschienen in
Psychiatric Quarterly / Ausgabe 3/2010
Print ISSN: 0033-2720
Elektronische ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-010-9130-6

Weitere Artikel der Ausgabe 3/2010

Psychiatric Quarterly 3/2010 Zur Ausgabe

ORIGINAL PAPER

Toward Understanding Errors in Inpatient Psychiatry: A Qualitative Inquiry

Original Paper

Aggression in Borderline Personality Disorder

Original Paper

‘The Human Prerogative’: A Critical Analysis of Evidence-Based and Other Paradigms of Care in Substance Abuse Treatment

Original Paper

Overlapping Universe: Understanding Legal Insanity and Psychosis

Original Paper

Psychiatric Correlates of Bullying in the United States: Findings from a National Sample

Original Paper

Interdisciplinary Treatment Planning in Inpatient Settings: From Myth to Model

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise